340023-04-3

Basic information

• Product Name: 1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid
• Synonyms: 1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid;1-Vinyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid
• CAS NO: 340023-04-3
• Molecular Weight: 182.219
• Mol File: 340023-04-3.mol

Chemical Properties

• CAS DataBase Reference: 1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid(340023-04-3)
• EPA Substance Registry System: 1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid(340023-04-3)

Safety Data

• Hazardous Substances Data: 340023-04-3(Hazardous Substances Data)

Usage

Molecular Structure

1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid has a complex molecular structure, featuring a bicyclic ring system with an ethenyl group attached to one of the carbon atoms.

Carboxylic Acid Derivative

1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid is a derivative of carboxylic acid, which means it contains a carboxyl functional group (-COOH) attached to a carbon chain.

Bicyclic Ring System

The compound features a unique bicyclic ring system, which consists of two fused rings within the molecule. In this case, the bicyclic system is formed by an eight-membered ring and a three-membered ring.

Ethenyl Group

The presence of an ethenyl group (a vinyl group with a double bond) in the structure contributes to the compound's unique properties and potential applications.

Potential Applications

Due to its unique structure and functional groups, 1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid may have potential uses in various fields, such as pharmaceuticals, materials science, and other industries.

Further Research

To fully understand the properties and potential applications of 1-ethenyl-2-oxabicyclo[2.2.2]octane-4-carboxylic acid, additional research and experimentation may be necessary. This includes studying its chemical reactivity, stability, and interactions with other compounds or materials.

Upstream product

• 340023-03-2 (1-vinyl-2-oxabicyclo[2.2.2]octan-4-yl)methanol 
• 57899-62-4 triethyl 4-oxocyclohexane-1,1,3-tricarboxylate 
• 55704-60-4 4-oxo-cyclohexane-1,1-dicarboxylic acid diethyl ester 
• 1256546-71-0 8,8-diethyl 1,4-dioxaspiro[4.5]decane-8,8-dicarboxylate 
• 1257050-69-3 1,4-dioxaspiro[4.5]decane-8,8-diylbis(methylene) bis(4-methylbenzenesulfonate) 
• 340022-81-3 (4-oxocyclohexane-1,1-diyl)bis(methylene) bis(4-methylbenzenesulfonate) 
• 340023-02-1 (1-vinyl-2-oxabicyclo[2.2.2]octan-4-yl)methyl acetate 
• 1256546-72-1 [8-(hydroxymethyl)-1,4-dioxaspiro[4.5]decan-8-yl]methanol 

Downstream Products

• 1417551-42-8 tert-butyl N-(4-formyl-3-oxabicyclo[2.2.2]octan-1-yl)carbamate 
• 1416374-98-5 tert-butyl (1-ethenyl-2-oxabicyclo[2.2.2]oct-4-yl)carbamate 
• 1616409-89-2 t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate 
• 1616409-88-1 t-butyl 1-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)-1-hydroxyethyl)-2-oxabicyclo[2.2.2]octan-4-ylcarbamate 

Relevant articles and documents

Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents

Bacterial resistance is eroding the clinical utility of existing antibiotics necessitating the discovery of new agents. Bacterial type II topoisomerase is a clinically validated, highly effective, and proven drug target. This target is amenable to inhibit

Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists

An X-ray crystal structure of one of our previously discovered RORγt inverse agonists bound to the RORγt ligand binding domain revealed that the cyclohexane carboxylic acid group of compound 2 plays a significant role in RORγt binding, forming four hydrog

BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

Adenosine receptor antagonists and methods of making and using the same

The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1receptor. Adenosine A1antagonists can be usefull in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable. In one embodiment, the invention features a compound of formula I: wherein: R3is an optionally substituted bicyclic, tricylic, or pentacyclic group selected from: ?and wherein R1, R2, R6, X1, X2, and Z are as described in the specification.